Debiopharm has dosed the first patient in a Phase I clinical trial of Debio 0123 combined with carboplatin and etoposide to treat recurrent or progressive small cell lung cancer (SCLC) in patients following a standard platinum-based chemotherapy.
The first patient was dosed at Vall d’Hebron Hospital in Barcelona, Spain.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The multicentre, open-label study includes a dose escalation phase for identifying the recommended dose and an expansion phase to characterise the tolerability, safety, and initial signal of antitumoural activity of the combined therapy.
Debiopharm Oncology Research & Development senior medical director Dr Esteban Rodrigo Imedio said: “This combination might succeed in strategically enhancing antitumoural activity and delay the resistance to carboplatin and etoposide combination in patients with recurrent SCLC.”
Debio 0123 is an oral, potent and brain penetrant WEE1 inhibitor that regulates the G2/M and S phase checkpoints allowing repair of cells’ DNA before resuming their cycle.
When combined with DNA damaging agents, WEE1 inhibition induces an overload of DNA breaks.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDebio 0123 is being developed to address high unmet needs of patients living with the burden of cancers that are difficult to treat.
Debiopharm combines Debio 0123 and standard-of-care treatment to short-circuit DNA damage repair in adult patients with recurrent or progressive SCLC.
